Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (1411-1420 of 1,779) with videos related to

Pageof 178
Sort By:
Mabs|February 28, 2018
When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regionsAndrew R M Bradbury, Nathan D Trinklein, Holger Thie, et al.
Mabs|January 3, 2018
Challenges and new frontiers in analytical characterization of antibody-drug conjugatesAnil Wagh, Hangtian Song, Ming Zeng, et al.
Mabs|November 28, 2019
Defining the right diluent for intravenous infusion of therapeutic antibodiesShen Luo, Keisha Melodi McSweeney, Tao Wang, et al.
Mabs|November 29, 2019
Structure-based engineering of pH-dependent antibody binding for selective targeting of solid-tumor microenvironmentTraian Sulea, Nazanin Rohani, Jason Baardsnes, et al.
Mabs|November 28, 2017
Engineered aglycosylated full-length IgG Fc variants exhibiting improved FcγRIIIa binding and tumor cell clearanceMigyeong Jo, Hyeong Sun Kwon, Kwang-Hoon Lee, et al.
Mabs|November 28, 2017
Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector functionOliver Popp, Samuel Moser, Jörg Zielonka, et al.
Mabs|November 30, 2017
Monoclonal antibodies targeting the disintegrin-like domain of ADAMDEC1 modulates the proteolytic activity and enables quantification of ADAMDEC1 protein in human plasmaJacob Lund, Anne Mette Elimar Bitsch, Morten Grønbech Rasch, et al.
Mabs|December 1, 2017
Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney diseaseXiaoying Chen, Vahid Farrokhi, Pratap Singh, et al.
Mabs|November 15, 2017
Hydrogen/deuterium exchange mass spectrometry and computational modeling reveal a discontinuous epitope of an antibody/TL1A InteractionRichard Y-C Huang, Stanley R Krystek, Nathan Felix, et al.
Mabs|January 31, 2019
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodiesNathan D Trinklein, Duy Pham, Ute Schellenberger, et al.
Pageof 178

Showing results (1411-1420 of 1,779) with videos related to

Sort By:
Pageof 178
Mabs|February 28, 2018
When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regionsAndrew R M Bradbury, Nathan D Trinklein, Holger Thie, et al.
Mabs|January 3, 2018
Challenges and new frontiers in analytical characterization of antibody-drug conjugatesAnil Wagh, Hangtian Song, Ming Zeng, et al.
Mabs|November 28, 2019
Defining the right diluent for intravenous infusion of therapeutic antibodiesShen Luo, Keisha Melodi McSweeney, Tao Wang, et al.
Mabs|November 29, 2019
Structure-based engineering of pH-dependent antibody binding for selective targeting of solid-tumor microenvironmentTraian Sulea, Nazanin Rohani, Jason Baardsnes, et al.
Mabs|November 28, 2017
Engineered aglycosylated full-length IgG Fc variants exhibiting improved FcγRIIIa binding and tumor cell clearanceMigyeong Jo, Hyeong Sun Kwon, Kwang-Hoon Lee, et al.
Mabs|November 28, 2017
Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector functionOliver Popp, Samuel Moser, Jörg Zielonka, et al.
Mabs|November 30, 2017
Monoclonal antibodies targeting the disintegrin-like domain of ADAMDEC1 modulates the proteolytic activity and enables quantification of ADAMDEC1 protein in human plasmaJacob Lund, Anne Mette Elimar Bitsch, Morten Grønbech Rasch, et al.
Mabs|December 1, 2017
Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney diseaseXiaoying Chen, Vahid Farrokhi, Pratap Singh, et al.
Mabs|November 15, 2017
Hydrogen/deuterium exchange mass spectrometry and computational modeling reveal a discontinuous epitope of an antibody/TL1A InteractionRichard Y-C Huang, Stanley R Krystek, Nathan Felix, et al.
Mabs|January 31, 2019
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodiesNathan D Trinklein, Duy Pham, Ute Schellenberger, et al.
Pageof 178